[le comité exécutif d'Unitaid a décidé de mettre 138 millions de dollars
* pour le développement de leur projet "medicines patent pool",
* pour les traitements des enfants VIH (62 millions de dollars à la
Fondation Clinton)
* pour augmenter l'accès aux ACT (50 millions de dollars au Fonds
Mondial.CB]
UNITAID continues funding for medicines patent pool and paediatric AIDS
medicines
http://www.unitaid.eu/fr/resources/actualites/380-additional-us-50-million-a
llotted-to-malaria
There are no translations available.
Additional US$ 50 Million Allotted to Malaria
Geneva, 14 December 2011 At its meeting in Paris on 12-13 December, the
UNITAID Executive Board demonstrated its continued commitment to scaling up
access for HIV/AIDS and malaria by allocating an extra US$ 138 million to
the two diseases.
UNITAID will provide funding support over the next four years for the
Medicines Patent Pool to negotiate voluntary licences from brand companies
to generic manufacturers to facilitate affordable access to HIV/AIDS
medicines in developing countries.
"Precisely because funding for AIDS is threatened by the economic crisis, we
need to leverage all the tools at our disposal to ensure staunch commitment
to increase treatment coverage," said Philippe Douste-Blazy, Chairman of the
UNITAID Executive Board. "Innovative mechanisms that can increase treatment
availability and decrease prices, such as the Pool, are critical components
of UNITAID's AIDS treatment strategy to address the funding gap".
The Board resolution on this issue reiterates UNITAID's position that the
Pool should seek a broad geographical scope to include low- and
middle-income countries as potential beneficiaries of the licenses.
"Because the Pool is a voluntary mechanism, its ultimate success depends on
the willingness of patent holders to share their technology in ways that
allow as many people in developing countries as possible to benefit," added
Philippe Douste-Blazy. "The Pool has achieved promising results in its
first year and we urge all pharmaceutical companies to enter into licensing
agreements to breach the gap of 15 million people who need treatment."
The UNITAID Board also committed US$ 62 million to continue supporting the
scale-up of HIV/AIDS treatment for children in partnership with the Clinton
Health Access Initiative. The partnership, which covers about 85% of
paediatric AIDS treatment, has been successful in promoting child-friendly
medicines by ensuring long-term, high-volume drug purchases which have
reduced the cost of the medicines by as much as 80%.
An additional US$ 50 million were committed to the Global Fund to increase
access to artemisinin-based combination therapy (the best known treatment
for malaria today) in the eight African countries that bear the largest
malaria burden.
Contact: Daniela Bagozzi,
Tel. +41 22 791 45 44;
Mob. +41 79 475 54 90;
Email bagozzid@who.int